The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•8 April 2026•

1 min read

Ascent Group Increases Stake in Johnson & Johnson Amid Positive Analyst Outlook

Key Facts

1Ascent Group LLC increased its stake in Johnson & Johnson by 7.2% in the fourth quarter, reaching a value of $14.07 million.

2Total insider selling at the company amounted to over $7.36 million in the last ninety days.

3Analysts currently rate the stock as a 'Moderate Buy' with a consensus price target of $237.57.

Ascent Group LLC expanded its position in Johnson & Johnson (JNJ) by 7.2% during the fourth quarter. The investment firm now holds shares valued at approximately $14.07 million, reflecting growing institutional confidence in the healthcare giant. This move comes despite significant insider selling activity, which totaled over $7.36 million within the last 90 days. Market analysts currently maintain a "Moderate Buy" rating on the stock, citing strong commercial milestones and long-term potential. The consensus price target for JNJ stands at $237.57, suggesting a substantial upside from current market levels. Institutional rebalancing remains a key driver for the stock as investors weigh fundamental growth against recent insider transactions.

Create Free Account